# Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

> **NCT03161353** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MedSIR** · enrollment: 377 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Perjeta
- **DRUG:** Herceptin
- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Letrozole
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT03161353
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-26
- **Primary completion:** 2023-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 377 (ACTUAL)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03161353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03161353, "Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03161353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*